- Email: [email protected]
New gene fragment encoding rabies virus glycoprotein; DNA sequence expression in eukaryote cell culture and application to recombinant vaccine construction
Potent I eport This section provides information on worldwide patents relevant to vaccine design and production. The Patent Report gives the following information: title of patent, patentee, patent number, publication date and summary of the patent. A number of patents in this report are reproduced from 'Biotechnology Abstracts' with permission of Derwent Publications Ltd, Rochdale House, 128 Theobalds Road, London WC1X 8RP, UK.
Vaccine comprising anti-idiotype antibody conjugate; induces production of neutralizing antibody (human monoclonal antibody, chimeric antibody or FAb, F(Ab')2 or Fv fragment) against HIV virus-I Tenox Biosyst World 9208 491 ; 29 May 1992 Epitope-directed immunization is performed using a vaccine that includes an anti-idiotype antibody (I) conjugated to a carrier. The carrier is a protein against which the vaccine recipient has previously been exposed or is a peptide containing determinants recognized by the antigen-specific receptors on the T helper cells, or an antibody which enhances the immune response against the anti-idiotype. ( | ) preferably induces production of neutralizing antibodies against HIV virus-l, and the carrier is hepatitis B virus surface antigen (HBsAg), HIV-1 p24, or a T helper peptide derived from HBsAg or HIV-1 p24. (I) preferably induces production of neutralizing antibodies against the external envelope glycoprotein gpl20 of HIV-1, and especially against the principal neutralizing determinant of gp120. (I)is a human monoclonal (hmAb) antibody, especially a chimeric antibody having portions of its complementarity determining region derived from an animal (mouse) and other portions of its variable region, and its entire constant region, from a human. The vaccine especially comprises hmAb Fab, F ( a b ' ) 2 or Fv fragments. Specifically claimed is hmAb AB 19-4. 105-92
Antigen composition comprising PEB1 and/or PEB3 antigen from Campylobaeterjejuni; useful as vaccine and for diagnosis of C. jejuni and Campylobacter coli infections Blaser M J World 9208 485; 29 May 1992" An antigenic composition is claimed comprising the PEB1 antigen of Camplylobacterjejuni, which has a mol wt. of 28 000 (reducing SDS-PAGE) or 28 900 _ 1000 (native gel filtration) and a pI of 8.5, and is present at a concentration higher than that resulting from acid extraction from whole C. jejuni cells. Also claimed is a vaccine against C. jejuni and Campylobacter coli infection, comprising the PEB1 antigen at a concentration effective to induce the production of protective antibodies against C. jejuni and C. coli by animals. The vaccine may further comprise the C. jejuni PEB3 antigen (mol wt. 30000 (reducing SDS-PAGE) and pI greater than 9.3). Diagnostic detection kits include the novel antigenic composition or antisera. The antigens can be used for the highly specific and highly sensitive detection of C. jejuni or C. coli diarrhoeal infection. They can also be used in vaccines to protect against C. jejuni and C. coli infection in e.g. humans or livestock. Antisera (claimed) can be used for the detection of C. jejuni or C. coli. 106-92 0264410X/92/141059~)2 ,V, 1992 Butterworth-HeinemannLtd
Nucleic acid constructs, malaria polypeptides and vaccines; recombinant malaria serine-repeat antigen production in yeast for the construction of a recombinant vaccine Chiron World 9208 795 ; 29 May 1992 The following are claimed : i. a nucleic acid construct comprising a first domain encoding ubiquitin (Ub) and a second domain encoding a malaria peptide, e.g. a serine-repeat antigen (SERA), or an epitope-containing fragment, where the second domain is located downstream from the first domain, the construct may further comprise a third domain encoding a immunomodulator polypeptide, e.g. human interferon-gamma, where the third domain is located between the first and second domains; ii. a host cell transformed by a construct as in (i.); iii. a fusion polypeptide comprising a first immunomodulator polypeptide and a second malaria polypeptide; iv. an immunogenic composition comprising an immunogenic amount of SERA admixed with a vehicle ; and iv. an immunoassay for detecting antibodies directed against a malaria antigen. Nucleic acid constructs as in (i.) can be used to increase the level of expression of recombinant malaria polypeptides or epitope-containing fragments in host cells, particularly yeast. The malaria polypeptides can be used to produce antiserum, in vaccines or for diagn6qs. 107 92
New gene fragment encoding rabies virus glycoprotein; DNA sequence expression in eukaryote cell culture and application to recombinant vaccine construction Kagaku Oyobi Kessei Royoho Kenkyusho Jpn 4121 191 ; 22 April 1992 A gene fragment (II) and a rabies virus recombinant glycoprotein (I) are claimed. (II) encodes an antigenic protein (mol wt. approximately 48 000) which can induce a neutralizing antibody against the rabies virus. (I) is obtained by expression of (II) in a eukaryotic cell, from a shuttle vector containing (II) integrated downstream of a promoter functional in the eukaryotic cell. (II) contains a deletion of part of the Y-terminal region and/or part of the 5'-terminal region encoding (I). The partly deleted gene fragment contains at least nucleotides 55 1348 of (ll) in a specified DNA sequence. (I) may be effective as a rabies virus recombinant vaccine. The C-terminal deleted glycoprotein can also produce a neutralizing antibody. The expressed product does not contain any hydrophobic regions, and it can be extracted and purified as easily as in the solubilized stage. As its mol wt. is lower than native (I), the burden to the host is reduced, proliferation of (I) can occur as in the original host and large-scale production of(l ) is possible. 108-92
Recombinant feline corona virus-S protein; expressed as galactokinase fusion protein and useful as reconbinant vaccine, therapeutic and diagnostic agents for feline-infectious-peritonitis virus SK + Beecham World 9208 487; 29 May 1992 The following are claimed: a peptide or protein (A) useful in the diagnosis, treatment or prophylaxis (DTP) of a corona
Vaccine, Vol. 10, Issue 14, 1992
1059
Vaccine comprising anti-idiotype antibody conjugate; induces production of neutralizing antibody (human monoclonal antibody, chimeric antibody or FAb, F(Ab')2 or Fv fragment) against HIV virus-I Tenox Biosyst World 9208 491 ; 29 May 1992 Epitope-directed immunization is performed using a vaccine that includes an anti-idiotype antibody (I) conjugated to a carrier. The carrier is a protein against which the vaccine recipient has previously been exposed or is a peptide containing determinants recognized by the antigen-specific receptors on the T helper cells, or an antibody which enhances the immune response against the anti-idiotype. ( | ) preferably induces production of neutralizing antibodies against HIV virus-l, and the carrier is hepatitis B virus surface antigen (HBsAg), HIV-1 p24, or a T helper peptide derived from HBsAg or HIV-1 p24. (I) preferably induces production of neutralizing antibodies against the external envelope glycoprotein gpl20 of HIV-1, and especially against the principal neutralizing determinant of gp120. (I)is a human monoclonal (hmAb) antibody, especially a chimeric antibody having portions of its complementarity determining region derived from an animal (mouse) and other portions of its variable region, and its entire constant region, from a human. The vaccine especially comprises hmAb Fab, F ( a b ' ) 2 or Fv fragments. Specifically claimed is hmAb AB 19-4. 105-92
Antigen composition comprising PEB1 and/or PEB3 antigen from Campylobaeterjejuni; useful as vaccine and for diagnosis of C. jejuni and Campylobacter coli infections Blaser M J World 9208 485; 29 May 1992" An antigenic composition is claimed comprising the PEB1 antigen of Camplylobacterjejuni, which has a mol wt. of 28 000 (reducing SDS-PAGE) or 28 900 _ 1000 (native gel filtration) and a pI of 8.5, and is present at a concentration higher than that resulting from acid extraction from whole C. jejuni cells. Also claimed is a vaccine against C. jejuni and Campylobacter coli infection, comprising the PEB1 antigen at a concentration effective to induce the production of protective antibodies against C. jejuni and C. coli by animals. The vaccine may further comprise the C. jejuni PEB3 antigen (mol wt. 30000 (reducing SDS-PAGE) and pI greater than 9.3). Diagnostic detection kits include the novel antigenic composition or antisera. The antigens can be used for the highly specific and highly sensitive detection of C. jejuni or C. coli diarrhoeal infection. They can also be used in vaccines to protect against C. jejuni and C. coli infection in e.g. humans or livestock. Antisera (claimed) can be used for the detection of C. jejuni or C. coli. 106-92 0264410X/92/141059~)2 ,V, 1992 Butterworth-HeinemannLtd
Nucleic acid constructs, malaria polypeptides and vaccines; recombinant malaria serine-repeat antigen production in yeast for the construction of a recombinant vaccine Chiron World 9208 795 ; 29 May 1992 The following are claimed : i. a nucleic acid construct comprising a first domain encoding ubiquitin (Ub) and a second domain encoding a malaria peptide, e.g. a serine-repeat antigen (SERA), or an epitope-containing fragment, where the second domain is located downstream from the first domain, the construct may further comprise a third domain encoding a immunomodulator polypeptide, e.g. human interferon-gamma, where the third domain is located between the first and second domains; ii. a host cell transformed by a construct as in (i.); iii. a fusion polypeptide comprising a first immunomodulator polypeptide and a second malaria polypeptide; iv. an immunogenic composition comprising an immunogenic amount of SERA admixed with a vehicle ; and iv. an immunoassay for detecting antibodies directed against a malaria antigen. Nucleic acid constructs as in (i.) can be used to increase the level of expression of recombinant malaria polypeptides or epitope-containing fragments in host cells, particularly yeast. The malaria polypeptides can be used to produce antiserum, in vaccines or for diagn6qs. 107 92
New gene fragment encoding rabies virus glycoprotein; DNA sequence expression in eukaryote cell culture and application to recombinant vaccine construction Kagaku Oyobi Kessei Royoho Kenkyusho Jpn 4121 191 ; 22 April 1992 A gene fragment (II) and a rabies virus recombinant glycoprotein (I) are claimed. (II) encodes an antigenic protein (mol wt. approximately 48 000) which can induce a neutralizing antibody against the rabies virus. (I) is obtained by expression of (II) in a eukaryotic cell, from a shuttle vector containing (II) integrated downstream of a promoter functional in the eukaryotic cell. (II) contains a deletion of part of the Y-terminal region and/or part of the 5'-terminal region encoding (I). The partly deleted gene fragment contains at least nucleotides 55 1348 of (ll) in a specified DNA sequence. (I) may be effective as a rabies virus recombinant vaccine. The C-terminal deleted glycoprotein can also produce a neutralizing antibody. The expressed product does not contain any hydrophobic regions, and it can be extracted and purified as easily as in the solubilized stage. As its mol wt. is lower than native (I), the burden to the host is reduced, proliferation of (I) can occur as in the original host and large-scale production of(l ) is possible. 108-92
Recombinant feline corona virus-S protein; expressed as galactokinase fusion protein and useful as reconbinant vaccine, therapeutic and diagnostic agents for feline-infectious-peritonitis virus SK + Beecham World 9208 487; 29 May 1992 The following are claimed: a peptide or protein (A) useful in the diagnosis, treatment or prophylaxis (DTP) of a corona
Vaccine, Vol. 10, Issue 14, 1992
1059